Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Anaplastic oligodendroglioma are chemotherapy-sensitive tumors. We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiotherapy (RT). Adult patients with newly diagnosed anapl...
Saved in:
| Published in | Journal of clinical oncology Vol. 31; no. 3; pp. 344 - 350 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Alexandria, VA
American Society of Clinical Oncology
20.01.2013
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0732-183X 1527-7755 1527-7755 |
| DOI | 10.1200/JCO.2012.43.2229 |
Cover
| Abstract | Anaplastic oligodendroglioma are chemotherapy-sensitive tumors. We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiotherapy (RT).
Adult patients with newly diagnosed anaplastic oligodendroglial tumors were randomly assigned to either 59.4 Gy of RT or the same RT followed by six cycles of adjuvant PCV. An exploratory analysis of the correlation between 1p/19q status and survival was part of the study. Retrospectively, the methylation status of the methyl-guanine methyl transferase gene promoter and the mutational status of the isocitrate dehydrogenase (IDH) gene were determined. The primary end points were overall survival (OS) and progression-free survival based on intent-to-treat analysis.
A total of 368 patients were enrolled. With a median follow-up of 140 months, OS in the RT/PCV arm was significantly longer (42.3 v 30.6 months in the RT arm, hazard ratio [HR], 0.75; 95% CI, 0.60 to 0.95). In the 80 patients with a 1p/19q codeletion, OS was increased, with a trend toward more benefit from adjuvant PCV (OS not reached in the RT/PCV group v 112 months in the RT group; HR, 0.56; 95% CI, 0.31 to 1.03). IDH mutational status was also of prognostic significance.
The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors. 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non-1p/19q-deleted tumors. |
|---|---|
| AbstractList | Anaplastic oligodendroglioma are chemotherapy-sensitive tumors. We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiotherapy (RT).
Adult patients with newly diagnosed anaplastic oligodendroglial tumors were randomly assigned to either 59.4 Gy of RT or the same RT followed by six cycles of adjuvant PCV. An exploratory analysis of the correlation between 1p/19q status and survival was part of the study. Retrospectively, the methylation status of the methyl-guanine methyl transferase gene promoter and the mutational status of the isocitrate dehydrogenase (IDH) gene were determined. The primary end points were overall survival (OS) and progression-free survival based on intent-to-treat analysis.
A total of 368 patients were enrolled. With a median follow-up of 140 months, OS in the RT/PCV arm was significantly longer (42.3 v 30.6 months in the RT arm, hazard ratio [HR], 0.75; 95% CI, 0.60 to 0.95). In the 80 patients with a 1p/19q codeletion, OS was increased, with a trend toward more benefit from adjuvant PCV (OS not reached in the RT/PCV group v 112 months in the RT group; HR, 0.56; 95% CI, 0.31 to 1.03). IDH mutational status was also of prognostic significance.
The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors. 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non-1p/19q-deleted tumors. Anaplastic oligodendroglioma are chemotherapy-sensitive tumors. We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiotherapy (RT).PURPOSEAnaplastic oligodendroglioma are chemotherapy-sensitive tumors. We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiotherapy (RT).Adult patients with newly diagnosed anaplastic oligodendroglial tumors were randomly assigned to either 59.4 Gy of RT or the same RT followed by six cycles of adjuvant PCV. An exploratory analysis of the correlation between 1p/19q status and survival was part of the study. Retrospectively, the methylation status of the methyl-guanine methyl transferase gene promoter and the mutational status of the isocitrate dehydrogenase (IDH) gene were determined. The primary end points were overall survival (OS) and progression-free survival based on intent-to-treat analysis.PATIENTS AND METHODSAdult patients with newly diagnosed anaplastic oligodendroglial tumors were randomly assigned to either 59.4 Gy of RT or the same RT followed by six cycles of adjuvant PCV. An exploratory analysis of the correlation between 1p/19q status and survival was part of the study. Retrospectively, the methylation status of the methyl-guanine methyl transferase gene promoter and the mutational status of the isocitrate dehydrogenase (IDH) gene were determined. The primary end points were overall survival (OS) and progression-free survival based on intent-to-treat analysis.A total of 368 patients were enrolled. With a median follow-up of 140 months, OS in the RT/PCV arm was significantly longer (42.3 v 30.6 months in the RT arm, hazard ratio [HR], 0.75; 95% CI, 0.60 to 0.95). In the 80 patients with a 1p/19q codeletion, OS was increased, with a trend toward more benefit from adjuvant PCV (OS not reached in the RT/PCV group v 112 months in the RT group; HR, 0.56; 95% CI, 0.31 to 1.03). IDH mutational status was also of prognostic significance.RESULTSA total of 368 patients were enrolled. With a median follow-up of 140 months, OS in the RT/PCV arm was significantly longer (42.3 v 30.6 months in the RT arm, hazard ratio [HR], 0.75; 95% CI, 0.60 to 0.95). In the 80 patients with a 1p/19q codeletion, OS was increased, with a trend toward more benefit from adjuvant PCV (OS not reached in the RT/PCV group v 112 months in the RT group; HR, 0.56; 95% CI, 0.31 to 1.03). IDH mutational status was also of prognostic significance.The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors. 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non-1p/19q-deleted tumors.CONCLUSIONThe addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors. 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non-1p/19q-deleted tumors. |
| Author | László Sipos Pim J. French Alba A. Brandes Martin J.B. Taphoorn Anouk Allgeier Martin J. van den Bent Thierry Gorlia Charles J. Vecht Cees C. Tijssen Wolfgang Grisold Johan M. Kros Roelien H. Enting Winand N.M. Dinjens Mathilde C.M. Kouwenhoven Khê Hoang-Xuan Marc Frenay Denis Lacombe Jean-Yves Delattre Hans J.J.A. Bernsen |
| Author_xml | – sequence: 1 givenname: Martin J. surname: van den Bent fullname: van den Bent, Martin J. organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 2 givenname: Alba A. surname: Brandes fullname: Brandes, Alba A. organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 3 givenname: Martin J.B. surname: Taphoorn fullname: Taphoorn, Martin J.B. organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 4 givenname: Johan M. surname: Kros fullname: Kros, Johan M. organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 5 givenname: Mathilde C.M. surname: Kouwenhoven fullname: Kouwenhoven, Mathilde C.M. organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 6 givenname: Jean-Yves surname: Delattre fullname: Delattre, Jean-Yves organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 7 givenname: Hans J.J.A. surname: Bernsen fullname: Bernsen, Hans J.J.A. organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 8 givenname: Marc surname: Frenay fullname: Frenay, Marc organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 9 givenname: Cees C. surname: Tijssen fullname: Tijssen, Cees C. organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 10 givenname: Wolfgang surname: Grisold fullname: Grisold, Wolfgang organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 11 givenname: László surname: Sipos fullname: Sipos, László organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 12 givenname: Roelien H. surname: Enting fullname: Enting, Roelien H. organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 13 givenname: Pim J. surname: French fullname: French, Pim J. organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 14 givenname: Winand N.M. surname: Dinjens fullname: Dinjens, Winand N.M. organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 15 givenname: Charles J. surname: Vecht fullname: Vecht, Charles J. organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 16 givenname: Anouk surname: Allgeier fullname: Allgeier, Anouk organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 17 givenname: Denis surname: Lacombe fullname: Lacombe, Denis organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 18 givenname: Thierry surname: Gorlia fullname: Gorlia, Thierry organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen – sequence: 19 givenname: Khê surname: Hoang-Xuan fullname: Hoang-Xuan, Khê organization: Martin J. van den Bent, Johan M. Kros, Mathilde C.M. Kouwenhoven, Roelien H. Enting, Pim J. French, and Winand N.M. Dinjens, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam; Martin J.B. Taphoorn and Charles J. Vecht, Medical Center Haaglanden, The Hague; Martin J.B. Taphoorn, Vrije Universiteit Medisch Centrum, Amsterdam; Hans J.J.A. Bernsen, Canisius Wilhelmina Ziekenhuis, Nijmegen; Cees C. Tijssen, St Elisabeth Hospital, Tilburg; Roelien H. Enting, University Medical Center Groningen, Groningen |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27077255$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23071237$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUtvEzEUhS1URB-wZ4W8QWLBBD_G9gy7NLQFFBEEKWJnOR5P4shjD_YMUfhJ_EqcNhUSC1a-sr5zdO855-DEB28AeI7RBBOE3nycLSYEYTIp6YQQUj8CZ5gRUQjB2Ak4Q4KSAlf0-yk4T2mLEC4ryp6AU0KRwISKM_B72mzHn8oP8HMMWsWV-mW9eQ3noRvTcDcq38Bv1uto7z7gbGO6MGxMVP0eWg8_mZ3bw3dWrX1IpoFTr3qnMqvhwtl1aIxvYlg7Gzr1Nhv7dbE0sYPXwbmwK257GFp4tfiynMHLqLLhcuxChDcxjD38OozNHhJeM_wUPG6VS-bZ8b0At9dXy9n7Yr64-TCbzgtdcjEUmFJWa95yVXLNa0oqU-aMVhSzfH2lqKKorFcVK0VjBMGUNRznDFuB2haxil6AV_e-fQw_RpMG2dmkjXPKmzAmiYmgvOZcsIy-OKLjqjON7KPtVNzLh3wz8PIIqKSVa6Py2qa_nEBCEHYw4vecjiGlaFqp7aAGG_yQI3ESI3koXObC5aFwWVJ5KDwL0T_CB-__SI47bex6s7PRyNQp5_IJRG51oFhSScuS_gEwOrhk |
| CitedBy_id | crossref_primary_10_1093_annonc_mdx547 crossref_primary_10_1007_s00066_015_0855_x crossref_primary_10_1007_s00234_022_03038_0 crossref_primary_10_1016_j_ejca_2020_06_018 crossref_primary_10_1148_radiol_2019191140 crossref_primary_10_1007_s11060_016_2211_0 crossref_primary_10_1007_s11060_014_1495_1 crossref_primary_10_1007_s11910_020_01040_8 crossref_primary_10_1200_JCO_19_02983 crossref_primary_10_1053_j_seminoncol_2014_06_009 crossref_primary_10_1093_neuonc_noab200 crossref_primary_10_1093_neuonc_noy016 crossref_primary_10_1053_j_seminoncol_2014_06_010 crossref_primary_10_1016_j_clon_2014_03_012 crossref_primary_10_1097_WCO_0000000000000866 crossref_primary_10_1007_s42451_020_00246_x crossref_primary_10_17116_neiro20238704146 crossref_primary_10_3390_ijms22020924 crossref_primary_10_1007_s00330_015_4025_4 crossref_primary_10_1038_s41571_020_00447_z crossref_primary_10_1080_14737140_2020_1757440 crossref_primary_10_1007_s00401_024_02802_1 crossref_primary_10_1016_j_nic_2020_09_011 crossref_primary_10_1200_JCO_21_02036 crossref_primary_10_1002_cncr_31039 crossref_primary_10_1016_j_crad_2021_06_015 crossref_primary_10_1155_2014_198697 crossref_primary_10_1007_s00701_014_2073_1 crossref_primary_10_1093_neuonc_nox176 crossref_primary_10_1093_neuonc_now085 crossref_primary_10_3389_fneur_2022_874826 crossref_primary_10_3389_fonc_2022_708272 crossref_primary_10_1111_epi_12453 crossref_primary_10_1016_j_neurol_2023_03_001 crossref_primary_10_3389_fonc_2023_1143688 crossref_primary_10_1016_j_tranon_2019_07_007 crossref_primary_10_1093_neuonc_nox146 crossref_primary_10_1016_j_wneu_2021_04_122 crossref_primary_10_1158_1078_0432_CCR_13_1157 crossref_primary_10_1002_cncr_32352 crossref_primary_10_1111_cxo_12416 crossref_primary_10_3389_fonc_2015_00055 crossref_primary_10_1016_j_clon_2014_04_026 crossref_primary_10_1007_s15015_013_0666_9 crossref_primary_10_1186_s12885_020_6536_x crossref_primary_10_3390_cancers14153705 crossref_primary_10_1016_j_clon_2014_04_024 crossref_primary_10_1093_jnen_nlw042 crossref_primary_10_14791_btrt_2023_0009 crossref_primary_10_1007_s11060_024_04891_0 crossref_primary_10_1007_s00415_013_7032_x crossref_primary_10_1053_j_seminoncol_2014_06_002 crossref_primary_10_14791_btrt_2023_0010 crossref_primary_10_1093_neuonc_nox158 crossref_primary_10_2217_cns_2017_0026 crossref_primary_10_1136_bmjopen_2024_097810 crossref_primary_10_1093_neuonc_nox153 crossref_primary_10_7887_jcns_23_46 crossref_primary_10_1093_neuonc_noz150 crossref_primary_10_1007_s11060_018_03059_x crossref_primary_10_1007_s11060_022_04049_w crossref_primary_10_7887_jcns_33_90 crossref_primary_10_1007_s11060_024_04829_6 crossref_primary_10_1158_1078_0432_CCR_22_1133 crossref_primary_10_3390_cancers12123825 crossref_primary_10_3892_ol_2018_9634 crossref_primary_10_1016_j_ejca_2018_02_023 crossref_primary_10_3174_ajnr_A6102 crossref_primary_10_1007_s13546_015_1073_3 crossref_primary_10_1007_s15005_018_2575_0 crossref_primary_10_1016_j_jmoldx_2016_10_010 crossref_primary_10_1016_j_wneu_2017_04_002 crossref_primary_10_3390_cells10051225 crossref_primary_10_1093_neuonc_noab006 crossref_primary_10_1111_apm_12916 crossref_primary_10_18632_oncotarget_2646 crossref_primary_10_18632_oncotarget_16773 crossref_primary_10_3390_cancers10110431 crossref_primary_10_1016_j_clon_2014_04_001 crossref_primary_10_6004_jnccn_2020_5008 crossref_primary_10_1200_EDBK_175003 crossref_primary_10_3892_ol_2017_7460 crossref_primary_10_1517_21678707_2014_928617 crossref_primary_10_1093_annonc_mdw013 crossref_primary_10_1093_neuonc_noaa168 crossref_primary_10_1002_14651858_CD011475_pub2 crossref_primary_10_1002_14651858_CD011475_pub3 crossref_primary_10_1093_neuonc_noz130 crossref_primary_10_1177_1533033818806498 crossref_primary_10_1158_1078_0432_CCR_24_0562 crossref_primary_10_1111_nan_12928 crossref_primary_10_2119_molmed_2017_00011 crossref_primary_10_1097_MD_0000000000041147 crossref_primary_10_1177_1535370220962715 crossref_primary_10_1007_s11060_022_04136_y crossref_primary_10_2217_cns_13_26 crossref_primary_10_1007_s11060_013_1152_0 crossref_primary_10_1007_s11060_014_1714_9 crossref_primary_10_1056_NEJMoa1407279 crossref_primary_10_3238_arztebl_2018_0356 crossref_primary_10_1016_j_gene_2018_08_001 crossref_primary_10_1007_s10014_014_0197_x crossref_primary_10_1007_s00115_014_4223_3 crossref_primary_10_1007_s11910_015_0611_8 crossref_primary_10_1093_neuonc_noab238 crossref_primary_10_1212_WNL_0000000000002014 crossref_primary_10_1212_CON_0000000000000935 crossref_primary_10_1007_s11060_015_1902_2 crossref_primary_10_1093_annonc_mdu050 crossref_primary_10_1016_j_gene_2019_02_073 crossref_primary_10_1016_j_ncl_2013_03_005 crossref_primary_10_1016_j_ctrv_2020_102124 crossref_primary_10_1055_s_0043_1776775 crossref_primary_10_1186_s13014_017_0782_3 crossref_primary_10_2174_1573394715666191017153045 crossref_primary_10_36290_neu_2021_040 crossref_primary_10_1007_s11060_020_03605_6 crossref_primary_10_1007_s00401_016_1611_8 crossref_primary_10_1200_EDBK_200989 crossref_primary_10_1093_neuonc_now236 crossref_primary_10_1016_j_soncn_2018_10_009 crossref_primary_10_3389_fneur_2018_01199 crossref_primary_10_1093_neuonc_nou297 crossref_primary_10_1186_s12885_021_07809_5 crossref_primary_10_1055_s_0043_1776764 crossref_primary_10_1007_s11940_013_0224_y crossref_primary_10_33920_med_01_2311_02 crossref_primary_10_1093_nop_npv033 crossref_primary_10_3390_ijms17060984 crossref_primary_10_1007_s11060_015_1822_1 crossref_primary_10_1310_hpj5202_98 crossref_primary_10_1007_s00761_018_0478_9 crossref_primary_10_1016_j_cll_2022_05_003 crossref_primary_10_1186_s12885_023_10594_y crossref_primary_10_3389_fncom_2019_00052 crossref_primary_10_1016_j_canrad_2014_07_147 crossref_primary_10_1007_s10014_013_0165_x crossref_primary_10_1186_s12885_022_09720_z crossref_primary_10_1002_14651858_CD007104_pub2 crossref_primary_10_1007_s00401_013_1156_z crossref_primary_10_1007_s11060_018_03072_0 crossref_primary_10_1093_noajnl_vdaa147 crossref_primary_10_1007_s00216_015_8891_z crossref_primary_10_1007_s11060_019_03376_9 crossref_primary_10_1002_14651858_CD011773_pub2 crossref_primary_10_1158_1078_0432_CCR_17_0560 crossref_primary_10_1093_neuonc_now210 crossref_primary_10_18632_oncotarget_17441 crossref_primary_10_1016_j_acra_2019_09_013 crossref_primary_10_1200_JCO_2017_72_6737 crossref_primary_10_1016_j_prro_2022_05_004 crossref_primary_10_1016_j_ejca_2018_03_016 crossref_primary_10_1007_s11864_013_0251_7 crossref_primary_10_1093_neuonc_nou047 crossref_primary_10_1093_neuonc_nov136 crossref_primary_10_1016_j_radonc_2022_08_020 crossref_primary_10_1055_a_1073_4578 crossref_primary_10_1016_j_radonc_2022_08_025 crossref_primary_10_1007_s11060_016_2217_7 crossref_primary_10_1016_j_cviu_2024_104100 crossref_primary_10_3389_fonc_2022_1060098 crossref_primary_10_1007_s00401_015_1432_1 crossref_primary_10_1007_s10072_021_05415_8 crossref_primary_10_1016_j_critrevonc_2024_104596 crossref_primary_10_1038_srep11593 crossref_primary_10_1016_j_clon_2024_05_005 crossref_primary_10_1227_01_neu_0000431477_02408_5e crossref_primary_10_1093_neuonc_now277 crossref_primary_10_1093_neuonc_nox124 crossref_primary_10_1007_s00432_021_03511_y crossref_primary_10_1093_neuonc_nox121 crossref_primary_10_1007_s40336_022_00489_6 crossref_primary_10_1093_neuonc_nov182 crossref_primary_10_1038_s41598_020_77777_6 crossref_primary_10_3389_fonc_2022_934426 crossref_primary_10_1007_s15015_017_2990_y crossref_primary_10_1016_j_canlet_2020_10_050 crossref_primary_10_1111_bpa_12788 crossref_primary_10_1038_ncb3429 crossref_primary_10_1093_noajnl_vdaa109 crossref_primary_10_3390_biomedicines13010201 crossref_primary_10_3109_0284186X_2015_1115123 crossref_primary_10_1097_RCT_0000000000000816 crossref_primary_10_1016_j_ncl_2018_04_005 crossref_primary_10_1093_neuonc_now285 crossref_primary_10_1093_neuonc_nox132 crossref_primary_10_1016_j_hoc_2021_08_006 crossref_primary_10_1016_j_hoc_2021_08_007 crossref_primary_10_1016_j_inat_2016_06_008 crossref_primary_10_3171_2017_7_PEDS17133 crossref_primary_10_1007_s12094_023_03245_y crossref_primary_10_1016_j_nec_2018_08_007 crossref_primary_10_1097_FS9_0000000000000031 crossref_primary_10_1038_nrneurol_2012_248 crossref_primary_10_1016_j_ejca_2014_06_016 crossref_primary_10_1007_s00115_013_3758_z crossref_primary_10_1016_j_cmpb_2022_107165 crossref_primary_10_3389_fneur_2020_551771 crossref_primary_10_3174_ajnr_A5070 crossref_primary_10_1093_neuonc_now014 crossref_primary_10_3389_fonc_2022_978427 crossref_primary_10_1186_s40478_020_00962_1 crossref_primary_10_1136_esmoopen_2017_000272 crossref_primary_10_1016_j_pharmthera_2013_05_003 crossref_primary_10_4236_jct_2021_128041 crossref_primary_10_1016_j_ijrobp_2018_08_025 crossref_primary_10_1007_s11864_024_01280_7 crossref_primary_10_1093_neuonc_now028 crossref_primary_10_1007_s11060_017_2418_8 crossref_primary_10_1038_s41582_022_00679_w crossref_primary_10_1093_neuonc_now268 crossref_primary_10_1007_s00428_021_03134_1 crossref_primary_10_1148_rg_2017170037 crossref_primary_10_1093_neuonc_noaa300 crossref_primary_10_1097_MD_0000000000036410 crossref_primary_10_1093_neuonc_nou083 crossref_primary_10_1155_2014_698542 crossref_primary_10_1017_cjn_2016_420 crossref_primary_10_1093_nop_npy012 crossref_primary_10_2217_cns_15_2 crossref_primary_10_1016_j_clineuro_2015_05_005 crossref_primary_10_1097_RCT_0000000000000742 crossref_primary_10_1148_radiol_2020191832 crossref_primary_10_1016_j_canrad_2021_08_006 crossref_primary_10_1093_neuonc_noac097 crossref_primary_10_1007_s10072_015_2332_9 crossref_primary_10_1186_s40478_021_01265_9 crossref_primary_10_1186_s40478_016_0331_6 crossref_primary_10_1007_s00066_019_01467_0 crossref_primary_10_3390_jcm10040645 crossref_primary_10_1186_s40478_018_0633_y crossref_primary_10_1186_s40644_022_00455_5 crossref_primary_10_1007_s00401_014_1315_x crossref_primary_10_1117_1_JMI_9_1_016001 crossref_primary_10_1007_s12254_013_0091_y crossref_primary_10_1002_cnr2_1181 crossref_primary_10_1007_s10014_022_00438_1 crossref_primary_10_3389_fonc_2014_00047 crossref_primary_10_1093_noajnl_vdz008 crossref_primary_10_1007_s11060_019_03344_3 crossref_primary_10_1093_neuonc_nou226 crossref_primary_10_1007_s11060_023_04244_3 crossref_primary_10_1016_j_clon_2023_11_027 crossref_primary_10_1093_nop_npy019 crossref_primary_10_1093_neuonc_nou224 crossref_primary_10_1016_j_jmoldx_2016_05_005 crossref_primary_10_1016_S1470_2045_18_30004_4 crossref_primary_10_3171_2022_1_FOCUS21596 crossref_primary_10_1016_j_rmclc_2017_05_003 crossref_primary_10_1016_j_rmclc_2017_05_007 crossref_primary_10_1007_s11060_024_04611_8 crossref_primary_10_22328_2079_5343_2022_13_4_102_108 crossref_primary_10_18632_oncotarget_4497 crossref_primary_10_1093_nop_npy032 crossref_primary_10_1016_j_clon_2018_06_005 crossref_primary_10_1016_j_ncl_2021_11_003 crossref_primary_10_3109_0284186X_2014_951492 crossref_primary_10_1016_j_ijrobp_2021_10_002 crossref_primary_10_1016_S1634_7072_24_49603_7 crossref_primary_10_1002_gcc_22323 crossref_primary_10_1007_s11060_017_2613_7 crossref_primary_10_1007_s11060_022_04217_y crossref_primary_10_3389_fneur_2021_644804 crossref_primary_10_3390_cancers14112762 crossref_primary_10_1007_s10143_014_0539_5 crossref_primary_10_1212_01_wnl_0000451452_30826_6b crossref_primary_10_18632_oncotarget_22500 crossref_primary_10_1007_s15004_020_8237_7 crossref_primary_10_1158_1078_0432_CCR_19_0299 crossref_primary_10_1002_pbc_26708 crossref_primary_10_1097_PPO_0000000000000758 crossref_primary_10_1016_j_trecan_2016_06_003 crossref_primary_10_1007_s11060_016_2054_8 crossref_primary_10_1016_j_mayocp_2017_01_010 crossref_primary_10_1093_nop_npy044 crossref_primary_10_1080_0284186X_2017_1332780 crossref_primary_10_1016_S1470_2045_23_00005_0 crossref_primary_10_1093_noajnl_vdab069 crossref_primary_10_1016_j_radonc_2024_110594 crossref_primary_10_1097_PPO_0000000000000760 crossref_primary_10_3390_cancers15123067 crossref_primary_10_1007_s13311_017_0519_x crossref_primary_10_3340_jkns_2013_54_6_489 crossref_primary_10_5812_ans_68874 crossref_primary_10_1007_s00401_021_02395_z crossref_primary_10_1097_CCO_0000000000000409 crossref_primary_10_1093_nop_npw034 crossref_primary_10_4143_crt_2019_520 crossref_primary_10_1016_j_wneu_2018_09_109 crossref_primary_10_1007_s10014_018_0324_1 crossref_primary_10_1517_13543784_2015_1048332 crossref_primary_10_3390_ph17060682 crossref_primary_10_34087_cbusbed_1112557 crossref_primary_10_1586_14737175_2015_1042455 crossref_primary_10_1007_s11910_023_01265_3 crossref_primary_10_1016_j_neurol_2015_04_002 crossref_primary_10_1097_NCC_0000000000000435 crossref_primary_10_3389_fcell_2021_756005 crossref_primary_10_1007_s40336_022_00507_7 crossref_primary_10_1016_j_neurol_2014_10_010 crossref_primary_10_7887_jcns_27_82 crossref_primary_10_1093_neuonc_nov118 crossref_primary_10_1093_neuonc_now207 crossref_primary_10_1186_s12885_018_4825_4 crossref_primary_10_1007_s10014_018_0313_4 crossref_primary_10_1016_j_radonc_2019_04_029 crossref_primary_10_3390_brainsci13111536 crossref_primary_10_1093_oncolo_oyac023 crossref_primary_10_14694_EdBook_AM_2013_33_108 crossref_primary_10_1080_2162402X_2020_1777625 crossref_primary_10_1007_s11060_017_2486_9 crossref_primary_10_1007_s11912_012_0282_4 crossref_primary_10_7759_cureus_70532 crossref_primary_10_7887_jcns_28_699 crossref_primary_10_3389_fonc_2018_00440 crossref_primary_10_1186_s11658_022_00354_4 crossref_primary_10_1200_JCO_2013_49_3726 crossref_primary_10_1007_s00701_020_04426_2 crossref_primary_10_1200_JCO_2016_67_1222 crossref_primary_10_1007_s11060_016_2241_7 crossref_primary_10_14694_EdBook_AM_2013_33_114 crossref_primary_10_4236_jct_2014_51010 crossref_primary_10_1016_j_pathol_2023_11_003 crossref_primary_10_1080_14737175_2016_1202761 crossref_primary_10_1093_neuonc_not159 crossref_primary_10_1007_s11060_013_1356_3 crossref_primary_10_1007_s11060_014_1660_6 crossref_primary_10_1371_journal_pone_0188419 crossref_primary_10_1007_s11060_014_1684_y crossref_primary_10_1016_S1634_7072_18_41587_5 crossref_primary_10_1186_2051_5960_2_68 crossref_primary_10_1038_nrdp_2015_17 crossref_primary_10_1212_CPJ_0b013e3182a1ba35 crossref_primary_10_1007_s42979_020_00214_y crossref_primary_10_1212_CON_0000000000001352 crossref_primary_10_1016_j_hoc_2019_08_015 crossref_primary_10_17116_neiro20218504196 crossref_primary_10_3389_fonc_2020_560211 crossref_primary_10_1002_pbc_26346 crossref_primary_10_1097_WCO_0000000000001316 crossref_primary_10_1007_s00401_014_1370_3 crossref_primary_10_1016_j_clineuro_2018_05_015 crossref_primary_10_1007_s00761_018_0481_1 crossref_primary_10_3174_ajnr_A5218 crossref_primary_10_1007_s11060_015_1906_y crossref_primary_10_1007_s11060_015_1883_1 crossref_primary_10_1007_s11864_019_0625_6 crossref_primary_10_1055_a_0803_5596 crossref_primary_10_1097_RMR_0000000000000234 crossref_primary_10_23736_S1824_4785_18_03105_9 crossref_primary_10_1016_j_canrad_2015_05_012 crossref_primary_10_1259_bjr_20160600 crossref_primary_10_1016_j_ijrobp_2017_02_223 crossref_primary_10_1016_j_jmoldx_2016_06_002 crossref_primary_10_3390_cancers13215398 crossref_primary_10_1515_biol_2021_0039 crossref_primary_10_1186_s12880_024_01262_z crossref_primary_10_2217_cns_14_30 crossref_primary_10_1001_jamaoncol_2022_2844 crossref_primary_10_1200_PO_21_00112 crossref_primary_10_1634_theoncologist_2014_0170 crossref_primary_10_1080_14737175_2019_1621169 crossref_primary_10_5306_wjco_v15_i2_178 crossref_primary_10_7748_cnp_2021_e1759 crossref_primary_10_1136_bmjopen_2021_054075 crossref_primary_10_1093_neuonc_noz063 crossref_primary_10_1016_j_critrevonc_2017_12_008 crossref_primary_10_1007_s11060_019_03315_8 crossref_primary_10_6004_jnccn_2020_0052 crossref_primary_10_1093_jnen_nlae119 crossref_primary_10_1016_j_jocn_2024_06_020 crossref_primary_10_3390_cancers15030618 crossref_primary_10_1200_JCO_23_02195 crossref_primary_10_1007_s00415_015_7919_9 crossref_primary_10_3389_fimmu_2019_02294 crossref_primary_10_1586_14737140_2015_1028376 crossref_primary_10_1016_j_clinme_2024_100240 crossref_primary_10_1016_j_humpath_2022_05_001 crossref_primary_10_1016_j_neucir_2022_08_001 crossref_primary_10_1200_EDBK_238353 crossref_primary_10_1515_raon_2015_0041 crossref_primary_10_3171_2019_6_JNS19409 crossref_primary_10_1056_NEJMc1605897 crossref_primary_10_1093_noajnl_vdz048 crossref_primary_10_1093_jjco_hyw142 crossref_primary_10_3390_cancers14051124 crossref_primary_10_3390_ph15080956 crossref_primary_10_1016_S1470_2045_13_70168_2 crossref_primary_10_3174_ajnr_A5421 crossref_primary_10_1093_noajnl_vdaf003 crossref_primary_10_1186_s40478_017_0465_1 crossref_primary_10_3174_ajnr_A5667 crossref_primary_10_1007_s11060_013_1278_0 crossref_primary_10_1016_j_wneu_2016_02_069 crossref_primary_10_1097_WCO_0000000000000257 crossref_primary_10_3389_fonc_2021_627202 crossref_primary_10_1007_s11864_018_0579_0 crossref_primary_10_1007_s00401_014_1326_7 crossref_primary_10_1007_s11060_016_2210_1 crossref_primary_10_1007_s11060_018_2985_3 crossref_primary_10_1097_RLU_0000000000002715 crossref_primary_10_1007_s11060_021_03776_w crossref_primary_10_1093_neuonc_noac031 crossref_primary_10_3174_ajnr_A6965 crossref_primary_10_1007_s11910_017_0722_5 crossref_primary_10_3934_dcdsb_2016028 crossref_primary_10_1007_s10278_017_9984_3 crossref_primary_10_1002_ima_22660 crossref_primary_10_1158_2767_9764_CRC_22_0436 crossref_primary_10_18632_oncotarget_25890 crossref_primary_10_1097_CCO_0000000000000236 crossref_primary_10_1007_s00234_015_1569_6 crossref_primary_10_3389_fnmol_2021_722396 crossref_primary_10_1093_neuonc_noae221 crossref_primary_10_1111_bpa_13062 crossref_primary_10_1097_MD_0000000000019416 crossref_primary_10_1097_CCO_0000000000000002 crossref_primary_10_1007_s00066_016_1016_6 crossref_primary_10_1097_CCO_0000000000000482 crossref_primary_10_1007_s00115_014_4242_0 crossref_primary_10_1007_s11060_021_03765_z crossref_primary_10_1148_radiol_232100 crossref_primary_10_1016_S1470_2045_16_30313_8 crossref_primary_10_1016_j_acra_2018_09_022 crossref_primary_10_1179_1743132814Y_0000000429 crossref_primary_10_2217_fon_2017_0598 crossref_primary_10_23736_S0390_5616_17_04045_0 crossref_primary_10_1007_s11060_016_2212_z crossref_primary_10_1016_j_critrevonc_2020_103062 crossref_primary_10_1007_s12094_017_1762_7 crossref_primary_10_4132_jptm_2017_09_25 crossref_primary_10_1007_s11060_020_03526_4 crossref_primary_10_1259_bjr_20150857 crossref_primary_10_1007_s11060_018_2908_3 crossref_primary_10_1111_neup_12789 crossref_primary_10_3389_frai_2021_635766 crossref_primary_10_1093_neuonc_noy131 crossref_primary_10_1097_WCO_0000000000000500 crossref_primary_10_1016_j_ijrobp_2020_05_043 crossref_primary_10_1155_2014_734281 crossref_primary_10_1038_s41598_022_10114_1 crossref_primary_10_1016_j_ijrobp_2015_10_032 crossref_primary_10_1016_j_ijrobp_2015_10_035 crossref_primary_10_1007_s11060_018_2919_0 crossref_primary_10_1007_s11060_024_04794_0 crossref_primary_10_3171_2019_9_FOCUS19660 crossref_primary_10_1016_j_ejcsup_2014_03_003 crossref_primary_10_1053_j_ro_2017_11_005 crossref_primary_10_1007_s00292_015_0002_6 crossref_primary_10_7887_jcns_23_547 crossref_primary_10_1097_COC_0000000000000519 crossref_primary_10_1007_s13402_019_00447_x crossref_primary_10_1038_ncomms11263 crossref_primary_10_1108_LHT_08_2019_0173 crossref_primary_10_1093_neuonc_now181 crossref_primary_10_1371_journal_pone_0306711 crossref_primary_10_1016_j_ijrobp_2014_07_046 crossref_primary_10_1007_s42451_021_00362_2 crossref_primary_10_1007_s15004_019_6384_5 crossref_primary_10_1007_s11060_024_04826_9 crossref_primary_10_1097_COC_0000000000000511 crossref_primary_10_1097_COC_0000000000000755 crossref_primary_10_1007_s12094_017_1631_4 crossref_primary_10_1093_nop_npae040 crossref_primary_10_3349_ymj_2023_0112 crossref_primary_10_1002_14651858_CD013387_pub2 crossref_primary_10_3389_fonc_2021_625838 crossref_primary_10_1200_JCO_2014_59_0166 crossref_primary_10_18632_oncotarget_4928 crossref_primary_10_1093_jncics_pkac010 crossref_primary_10_1200_EDBK_158869 crossref_primary_10_1155_2014_540236 crossref_primary_10_1186_s13000_019_0793_5 crossref_primary_10_1002_cncr_31371 crossref_primary_10_1007_s00066_020_01626_8 crossref_primary_10_1080_00207454_2018_1557165 crossref_primary_10_1158_1078_0432_CCR_15_0656 crossref_primary_10_1186_s12880_022_00865_8 crossref_primary_10_1016_j_acra_2022_10_009 crossref_primary_10_1016_j_jocn_2016_12_003 crossref_primary_10_1093_nop_npac045 crossref_primary_10_1093_neuonc_nox086 crossref_primary_10_1186_s13167_016_0063_5 crossref_primary_10_1016_j_jocn_2013_04_005 crossref_primary_10_1016_j_jocn_2014_01_011 crossref_primary_10_18632_oncotarget_3869 crossref_primary_10_1148_radiol_2017151930 crossref_primary_10_1093_neuonc_noy189 crossref_primary_10_1007_s15005_013_0305_1 crossref_primary_10_1093_neuonc_noac229 crossref_primary_10_1093_neuonc_noz033 crossref_primary_10_1038_s41598_017_19014_1 crossref_primary_10_1016_S0140_6736_17_31477_0 crossref_primary_10_1586_14737140_2015_1047351 crossref_primary_10_1007_s00401_015_1409_0 crossref_primary_10_1186_s12883_021_02548_3 crossref_primary_10_1093_neuonc_noy158 crossref_primary_10_12786_bn_2022_15_e24 crossref_primary_10_1016_j_isci_2018_10_011 crossref_primary_10_7887_jcns_24_366 crossref_primary_10_1016_j_mehy_2016_11_010 crossref_primary_10_1007_s10014_024_00480_1 crossref_primary_10_23736_S0390_5616_18_04610_6 crossref_primary_10_1159_000512562 crossref_primary_10_1186_1748_717X_8_187 crossref_primary_10_1016_S0140_6736_17_31442_3 crossref_primary_10_1038_nrneurol_2017_54 crossref_primary_10_1186_s13256_024_04757_z crossref_primary_10_18632_aging_101795 crossref_primary_10_1093_neuonc_noac202 crossref_primary_10_1093_neuonc_noaa022 crossref_primary_10_1093_neuonc_noz016 crossref_primary_10_1093_neuonc_noac207 crossref_primary_10_18632_oncotarget_12064 crossref_primary_10_1186_s12885_020_07290_6 crossref_primary_10_1007_s15004_013_0549_4 crossref_primary_10_1038_nrclinonc_2012_198 crossref_primary_10_1093_noajnl_vdaa044 crossref_primary_10_1136_esmoopen_2019_000534 crossref_primary_10_1007_s00701_014_2115_8 crossref_primary_10_1007_s11060_019_03122_1 crossref_primary_10_1080_23809000_2016_1136793 crossref_primary_10_1158_1078_0432_CCR_18_3101 crossref_primary_10_1016_S1470_2045_21_00090_5 crossref_primary_10_1200_JCO_2013_53_7076 crossref_primary_10_3389_fonc_2021_654350 crossref_primary_10_1016_j_clnu_2018_10_024 crossref_primary_10_1007_s11060_018_2915_4 crossref_primary_10_1016_j_path_2014_10_004 crossref_primary_10_1155_2020_1346340 crossref_primary_10_1007_s11136_014_0821_6 crossref_primary_10_1038_s41568_022_00475_0 crossref_primary_10_1007_s11060_015_1845_7 crossref_primary_10_3390_cancers15041042 crossref_primary_10_1097_MD_0000000000002583 crossref_primary_10_1007_s11060_015_2028_2 crossref_primary_10_1227_NEU_0000000000000753 crossref_primary_10_1158_1078_0432_CCR_13_3052 crossref_primary_10_1016_j_ctrv_2020_102029 crossref_primary_10_3390_app13063873 crossref_primary_10_1007_s11010_024_04976_4 crossref_primary_10_1002_cam4_2164 crossref_primary_10_1001_jamaoncol_2023_0990 crossref_primary_10_1093_nop_npw016 crossref_primary_10_7887_jcns_32_154 crossref_primary_10_1038_bjc_2014_538 crossref_primary_10_1158_1078_0432_CCR_14_0831 crossref_primary_10_1007_s11060_022_04026_3 crossref_primary_10_1212_WNL_0b013e3182a95680 crossref_primary_10_1158_1078_0432_CCR_14_0835 crossref_primary_10_1200_JCO_21_02543 crossref_primary_10_1016_j_pharmthera_2017_10_017 crossref_primary_10_18632_oncotarget_17322 crossref_primary_10_1007_s00062_024_01421_3 crossref_primary_10_1007_s00330_019_06548_3 crossref_primary_10_1007_s11060_024_04911_z crossref_primary_10_1016_j_mbs_2017_02_003 crossref_primary_10_1016_j_semradonc_2015_02_006 crossref_primary_10_1038_nrclinonc_2016_204 crossref_primary_10_1016_j_semradonc_2015_02_008 crossref_primary_10_1002_onco_13765 crossref_primary_10_1586_14737159_2014_945436 crossref_primary_10_1016_j_semradonc_2015_02_004 crossref_primary_10_1038_s41598_018_31806_7 crossref_primary_10_1515_revneuro_2022_0060 crossref_primary_10_1007_s00066_017_1199_5 crossref_primary_10_1038_s41586_020_2209_9 crossref_primary_10_1111_bpa_12434 crossref_primary_10_1016_j_wneu_2025_123716 crossref_primary_10_1038_nature16071 crossref_primary_10_1016_j_ejca_2013_06_039 crossref_primary_10_1038_s41698_024_00646_2 crossref_primary_10_1093_nop_npu009 crossref_primary_10_1007_s11910_024_01378_3 crossref_primary_10_1016_j_clineuro_2020_106303 crossref_primary_10_3171_2014_3_JNS131505 crossref_primary_10_1002_cam4_70016 crossref_primary_10_36290_neu_2016_060 crossref_primary_10_1093_neuonc_nox242 crossref_primary_10_1016_j_bbcan_2024_189102 crossref_primary_10_1111_1754_9485_12850 crossref_primary_10_1093_nop_npu023 crossref_primary_10_1007_s11060_018_03027_5 crossref_primary_10_1007_s00115_014_4226_0 crossref_primary_10_1007_s11060_021_03781_z crossref_primary_10_1093_neuonc_noaa200 crossref_primary_10_1007_s12254_016_0278_0 crossref_primary_10_1016_j_ctro_2018_12_003 crossref_primary_10_1016_j_xops_2024_100577 crossref_primary_10_1055_a_2298_4551 crossref_primary_10_18632_oncotarget_8498 crossref_primary_10_1016_j_jocn_2020_04_119 crossref_primary_10_1080_0284186X_2019_1670862 crossref_primary_10_3389_fonc_2021_621432 crossref_primary_10_1200_CCI_17_00022 crossref_primary_10_1093_neuonc_now133 crossref_primary_10_1200_JOP_18_00767 crossref_primary_10_1158_0008_5472_CAN_15_0776 crossref_primary_10_1016_j_celrep_2015_11_029 crossref_primary_10_1177_1756285617752039 crossref_primary_10_1016_j_critrevonc_2017_03_021 crossref_primary_10_1007_s11060_022_04202_5 crossref_primary_10_3171_2015_1_FOCUS14745 crossref_primary_10_1136_bmjopen_2022_070071 crossref_primary_10_3389_fcell_2021_760800 crossref_primary_10_1158_1078_0432_CCR_23_1295 crossref_primary_10_1016_j_ijrobp_2018_01_099 crossref_primary_10_1016_j_jocn_2014_10_004 crossref_primary_10_1016_j_radonc_2018_08_002 crossref_primary_10_1038_nrneurol_2013_268 crossref_primary_10_1186_s12883_023_03224_4 crossref_primary_10_1016_j_heliyon_2023_e23947 crossref_primary_10_1038_nrclinonc_2012_240 crossref_primary_10_1007_s11060_022_04216_z crossref_primary_10_3389_fonc_2021_746844 crossref_primary_10_1016_j_clon_2019_09_049 crossref_primary_10_1016_S1470_2045_17_30194_8 crossref_primary_10_1093_noajnl_vdac068 crossref_primary_10_1007_s00381_014_2563_8 crossref_primary_10_1007_s43440_024_00644_y crossref_primary_10_1200_JCO_2013_54_2878 crossref_primary_10_1177_1756286418790452 crossref_primary_10_1016_j_fmre_2021_07_005 crossref_primary_10_1080_14737175_2023_2285472 crossref_primary_10_1007_s11060_015_1909_8 crossref_primary_10_1056_NEJMoa1402121 crossref_primary_10_1007_s11912_024_01602_w crossref_primary_10_1186_s40478_017_0422_z crossref_primary_10_1016_j_cancergen_2023_08_005 crossref_primary_10_1016_S1470_2045_21_00154_6 crossref_primary_10_1007_s15004_016_5471_0 crossref_primary_10_1093_neuonc_nou108 crossref_primary_10_1097_RMR_0000000000000198 crossref_primary_10_1097_RMR_0000000000000197 crossref_primary_10_1097_RMR_0000000000000195 crossref_primary_10_2147_TCRM_S478905 crossref_primary_10_1111_nan_12031 crossref_primary_10_1093_noajnl_vdad142 crossref_primary_10_1177_0284185120973624 crossref_primary_10_1227_neu_0000000000001875 crossref_primary_10_1002_cam4_2686 crossref_primary_10_1016_j_semradonc_2017_11_001 crossref_primary_10_1007_s10014_021_00409_y crossref_primary_10_1200_JCO_24_00049 crossref_primary_10_1016_j_bspc_2021_103356 crossref_primary_10_1016_j_neucie_2022_11_006 crossref_primary_10_1093_neuonc_noac198 crossref_primary_10_1016_j_ejca_2014_05_019 crossref_primary_10_1007_s13311_017_0529_8 crossref_primary_10_1016_j_radonc_2022_03_018 crossref_primary_10_1016_j_rcl_2019_07_004 crossref_primary_10_1093_noajnl_vdad131 crossref_primary_10_3174_ng_2100034 crossref_primary_10_1080_0284186X_2020_1787507 crossref_primary_10_3174_ajnr_A5957 crossref_primary_10_1016_j_acra_2020_03_008 crossref_primary_10_1016_j_ctro_2023_100626 crossref_primary_10_1016_j_jocn_2018_11_005 crossref_primary_10_33920_med_01_2211_07 crossref_primary_10_1055_a_1133_1213 crossref_primary_10_1097_WCO_0000000000000390 crossref_primary_10_1111_bpa_12291 crossref_primary_10_1056_NEJMoa1500925 crossref_primary_10_1093_neuonc_not235 crossref_primary_10_1080_14737140_2016_1229600 crossref_primary_10_1016_j_clon_2016_11_006 crossref_primary_10_3390_cancers12071960 crossref_primary_10_1007_s10143_016_0709_8 crossref_primary_10_1016_j_ejca_2017_10_019 crossref_primary_10_1007_s11912_012_0283_3 crossref_primary_10_1007_s10637_017_0503_7 crossref_primary_10_1042_BSR20180005 crossref_primary_10_1093_neuonc_nou138 crossref_primary_10_12968_bjnn_2017_13_1_8 crossref_primary_10_1038_modpathol_2014_94 crossref_primary_10_1093_noajnl_vdac023 crossref_primary_10_1016_j_jocn_2015_05_038 crossref_primary_10_1016_S1470_2045_24_00130_X crossref_primary_10_1158_1078_0432_CCR_23_0585 crossref_primary_10_1002_ijc_33138 crossref_primary_10_1002_onco_13701 crossref_primary_10_1007_s12094_017_1790_3 crossref_primary_10_1080_07357907_2018_1430818 crossref_primary_10_3390_ijms232214224 crossref_primary_10_1007_s00401_015_1424_1 crossref_primary_10_1097_CCO_0000000000000785 crossref_primary_10_1007_s11060_013_1357_2 crossref_primary_10_1093_noajnl_vdac010 crossref_primary_10_3389_fgene_2022_720651 crossref_primary_10_1093_neuros_nyy433 crossref_primary_10_4143_crt_2019_421 crossref_primary_10_1007_s10147_020_01628_7 crossref_primary_10_1038_s41576_019_0171_x crossref_primary_10_1200_JCO_2012_44_4513 crossref_primary_10_1016_j_ijrobp_2014_10_027 crossref_primary_10_2174_0929867325666180706101404 crossref_primary_10_1101_mcs_a004119 crossref_primary_10_1111_nan_12246 crossref_primary_10_1038_modpathol_2013_165 crossref_primary_10_1016_j_semradonc_2014_06_005 crossref_primary_10_1007_s11060_017_2430_z crossref_primary_10_1111_cas_13635 crossref_primary_10_1093_noajnl_vdab146 crossref_primary_10_1093_neuonc_noae186 crossref_primary_10_1007_s10014_018_0312_5 crossref_primary_10_1007_s10072_014_1829_y crossref_primary_10_1093_neuonc_not036 crossref_primary_10_1097_COC_0000000000000380 crossref_primary_10_1016_j_jmoldx_2021_06_004 crossref_primary_10_2490_jjrmc_56_602 crossref_primary_10_2217_fon_2017_0634 crossref_primary_10_1093_nop_npac004 crossref_primary_10_1007_s00330_023_09459_6 crossref_primary_10_14791_btrt_2019_7_e42 crossref_primary_10_1007_s10278_024_00984_4 crossref_primary_10_17656_jsmc_10414 crossref_primary_10_2217_fon_2019_0764 crossref_primary_10_2217_cns_15_28 crossref_primary_10_1056_NEJMcpc1610101 crossref_primary_10_1586_14737140_2015_1062368 crossref_primary_10_1016_j_praneu_2014_07_002 crossref_primary_10_1080_14737159_2018_1548935 crossref_primary_10_1093_noajnl_vdae088 crossref_primary_10_1016_S0140_6736_18_31791_4 crossref_primary_10_3390_curroncol30090568 crossref_primary_10_2217_cns_15_25 crossref_primary_10_2217_cns_15_26 crossref_primary_10_1227_NEU_0000000000001019 crossref_primary_10_1016_j_radonc_2022_04_012 crossref_primary_10_1212_WNL_0000000000007126 crossref_primary_10_1007_s11060_019_03314_9 crossref_primary_10_1016_j_nicl_2019_101694 crossref_primary_10_1016_j_wneu_2022_10_063 crossref_primary_10_1007_s00401_015_1398_z crossref_primary_10_1016_j_radonc_2018_03_013 crossref_primary_10_1002_jmri_28793 crossref_primary_10_3390_cancers14030723 crossref_primary_10_2217_cns_15_32 crossref_primary_10_1080_13543784_2016_1182497 crossref_primary_10_2217_cns_15_35 crossref_primary_10_2217_cns_15_36 crossref_primary_10_1016_j_wneu_2024_04_111 crossref_primary_10_1093_nop_npaa072 crossref_primary_10_1093_nop_npaa073 crossref_primary_10_23736_S1824_4785_18_03096_0 crossref_primary_10_1038_s41598_020_63789_9 crossref_primary_10_1097_MPH_0000000000000610 crossref_primary_10_18632_oncotarget_24893 crossref_primary_10_1038_cgt_2015_39 crossref_primary_10_1111_nan_12447 crossref_primary_10_1093_neuonc_noac113 crossref_primary_10_1007_s11864_016_0430_4 crossref_primary_10_13104_imri_2018_22_3_158 crossref_primary_10_1007_s11060_013_1288_y crossref_primary_10_1007_s00401_013_1106_9 crossref_primary_10_1007_s11060_023_04417_0 crossref_primary_10_2217_cns_2016_0043 crossref_primary_10_1038_s41698_017_0036_8 crossref_primary_10_18632_aging_101594 crossref_primary_10_1080_2162402X_2018_1434466 crossref_primary_10_3389_fneur_2020_576230 crossref_primary_10_3389_fonc_2018_00373 crossref_primary_10_1001_jama_2023_0023 crossref_primary_10_3389_fonc_2018_00130 crossref_primary_10_1007_s11940_015_0369_y crossref_primary_10_1016_j_pmrj_2015_10_012 crossref_primary_10_1093_neuonc_noab279 crossref_primary_10_1093_neuonc_noy088 crossref_primary_10_1016_j_canrad_2016_07_008 crossref_primary_10_1016_j_neuchi_2017_07_003 crossref_primary_10_3389_fmolb_2022_806727 crossref_primary_10_18632_oncotarget_4549 crossref_primary_10_1007_s00259_017_3846_6 crossref_primary_10_1007_s00330_020_07581_3 crossref_primary_10_1016_S1470_2045_14_70011_7 crossref_primary_10_1016_j_jddst_2024_105721 crossref_primary_10_1007_s11060_024_04743_x crossref_primary_10_1016_j_neuroscience_2018_12_047 crossref_primary_10_1007_s11060_019_03316_7 crossref_primary_10_1007_s11060_014_1443_0 crossref_primary_10_1007_s00381_024_06487_5 crossref_primary_10_1016_j_radonc_2018_05_003 crossref_primary_10_1093_neuonc_noad038 crossref_primary_10_1002_jmri_29202 crossref_primary_10_1016_j_ejca_2021_11_017 crossref_primary_10_18632_oncotarget_5421 crossref_primary_10_1016_j_canlet_2016_01_024 crossref_primary_10_1016_j_tranon_2019_10_016 crossref_primary_10_1016_S0140_6736_18_30990_5 crossref_primary_10_1227_neu_0000000000003177 crossref_primary_10_1002_14651858_CD013387 crossref_primary_10_1097_CAD_0000000000001011 crossref_primary_10_1111_cns_70013 crossref_primary_10_1007_s11060_023_04515_z crossref_primary_10_1080_17425255_2020_1729352 crossref_primary_10_1016_j_clon_2015_04_008 crossref_primary_10_1038_s41572_024_00516_y crossref_primary_10_2174_1573394715666181129105542 crossref_primary_10_2217_cns_2016_0002 crossref_primary_10_1007_s00401_015_1439_7 crossref_primary_10_18632_oncotarget_11378 crossref_primary_10_18632_oncotarget_13555 crossref_primary_10_1136_jclinpath_2015_203456 crossref_primary_10_1093_neuonc_noae102 crossref_primary_10_1016_j_jocn_2022_10_026 crossref_primary_10_1016_j_lpm_2018_04_014 crossref_primary_10_1212_WNL_0000000000008877 |
| Cites_doi | 10.1212/WNL.51.4.1140 10.2353/ajpath.2009.080958 10.1200/JCO.2005.04.3414 10.1200/JCO.2007.12.7514 10.1200/JCO.1990.8.7.1277 10.1126/science.1164382 10.1200/JCO.1994.12.10.2013 10.1200/JCO.2009.27.1932 10.1007/s11060-010-0380-9 10.1016/j.ejca.2006.05.021 10.1215/15228517-2007-002 10.1007/s00401-010-0725-7 10.1007/s00401-008-0455-2 10.1016/S1474-4422(09)70204-2 10.1158/1078-0432.CCR-09-2902 10.1038/nature10860 10.1002/cncr.20611 10.1002/cncr.11187 10.1016/j.ccr.2010.03.017 10.1200/JCO.2009.24.1034 10.1016/j.ccr.2010.11.015 10.1111/j.1750-3639.2002.tb00440.x 10.1093/neuonc/noq110 10.1056/NEJMoa043331 10.1097/01.jnen.0000263869.84188.72 10.1111/j.1750-3639.2008.00129.x 10.1158/1078-0432.CCR-11-1274 10.1215/15228517-2009-011 10.1093/jnci/90.19.1473 10.1200/JCO.2009.23.6497 10.1200/JCO.2012.43.2674 10.1007/978-3-642-84988-6 10.1016/S0140-6736(04)17670-8 10.1038/nature10866 10.1200/JCO.2005.04.6078 10.2307/2344317 10.1002/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO;2-W |
| ContentType | Journal Article |
| Copyright | 2014 INIST-CNRS |
| Copyright_xml | – notice: 2014 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1200/JCO.2012.43.2229 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| EndPage | 350 |
| ExternalDocumentID | 23071237 27077255 10_1200_JCO_2012_43_2229 jco31_3_344 |
| Genre | Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MC_U122861383 |
| GroupedDBID | - 0R 2WC 34G 39C 4.4 53G 55 5GY 5RE 8F7 AAPEM AARDX AAWTL AAYEP ABFLS ABOCM ACDCL ACGFS ADBBV ADKWQ AENEX ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL CS3 DIK EBD EBS EJD F5P FD8 FH7 GX1 H13 HZ IH2 K-O KQ8 L7B LSO N9A O9- OK1 OVD OWW P2P RHI RUC SJN SV3 TWZ UDS WH7 X7M YCJ ZA5 --- .55 0R~ 18M AAYOK AAYXX ABBLC ABJNI ACGFO ACGUR AEGXH AIAGR C45 CITATION F9R FBNNL HZ~ MJL QTD R1G RLZ TEORI TR2 VVN YFH YQY .GJ 08G 08P 29K 3O- 5VS 8WZ A6W AAKAS AAQOH AAQQT ADZCM AFFNX AI. ASPBG AVWKF AZFZN BYPQX D-I EX3 FEDTE HVGLF IPNFZ IQODW J5H N4W NTWIH RIG UHU VH1 WOQ WOW ZGI CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c467t-13359c6f6a46c69328e4201b3154838a3a3049b8547de72135d61012f70ff0583 |
| ISSN | 0732-183X 1527-7755 |
| IngestDate | Fri Sep 05 03:58:11 EDT 2025 Mon Jul 21 06:07:41 EDT 2025 Mon Jul 21 09:16:31 EDT 2025 Thu Apr 24 22:59:58 EDT 2025 Tue Jul 01 01:11:38 EDT 2025 Tue Jan 05 20:16:30 EST 2021 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Antineoplastic agent Procarbazine Nervous system diseases Nitrosoureas Adjuvant treatment Early stage Long term Intracranial tumor Vincristine Anaplastic oligodendroglioma Cerebral disorder Alkylating agent Alkaloid Chemotherapy Treatment Cancerology Follow up study Nitrogen mustard Central nervous system disease Lomustine Antimitotic European Organization for Research and Treatment of Cancer |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c467t-13359c6f6a46c69328e4201b3154838a3a3049b8547de72135d61012f70ff0583 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2012.43.2229?role=tab |
| PMID | 23071237 |
| PQID | 1273696675 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_1273696675 pubmed_primary_23071237 pascalfrancis_primary_27077255 crossref_citationtrail_10_1200_JCO_2012_43_2229 crossref_primary_10_1200_JCO_2012_43_2229 highwire_smallpub2_jco31_3_344 |
| ProviderPackageCode | RHI CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-01-20 |
| PublicationDateYYYYMMDD | 2013-01-20 |
| PublicationDate_xml | – month: 01 year: 2013 text: 2013-01-20 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | Alexandria, VA |
| PublicationPlace_xml | – name: Alexandria, VA – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2013 |
| Publisher | American Society of Clinical Oncology |
| Publisher_xml | – name: American Society of Clinical Oncology |
| References | B20 B21 B22a B22 B23 B24 B25 B26 B27 B28 B29 B30 B31 B10 B32 B11 B33 B12 B34 B13 B35 B14 B36 B15 B16 B17 B18 B19 B1 B2 B3 B4 B5 B6 B7 B8 B9 23149899 - Nat Rev Clin Oncol. 2012 Dec;9(12):670. doi: 10.1038/nrclinonc.2012.198. |
| References_xml | – ident: B2 doi: 10.1212/WNL.51.4.1140 – ident: B25 doi: 10.2353/ajpath.2009.080958 – ident: B4 doi: 10.1200/JCO.2005.04.3414 – ident: B14 doi: 10.1200/JCO.2007.12.7514 – ident: B12 doi: 10.1200/JCO.1990.8.7.1277 – ident: B23 doi: 10.1126/science.1164382 – ident: B1 doi: 10.1200/JCO.1994.12.10.2013 – ident: B34 doi: 10.1200/JCO.2009.27.1932 – ident: B11 doi: 10.1007/s11060-010-0380-9 – ident: B22 doi: 10.1016/j.ejca.2006.05.021 – ident: B36 doi: 10.1215/15228517-2007-002 – ident: B15 doi: 10.1007/s00401-010-0725-7 – ident: B24 doi: 10.1007/s00401-008-0455-2 – ident: B35 doi: 10.1016/S1474-4422(09)70204-2 – ident: B8 doi: 10.1158/1078-0432.CCR-09-2902 – ident: B32 doi: 10.1038/nature10860 – ident: B21 doi: 10.1002/cncr.20611 – ident: B6 doi: 10.1002/cncr.11187 – ident: B27 doi: 10.1016/j.ccr.2010.03.017 – ident: B7 doi: 10.1200/JCO.2009.24.1034 – ident: B31 doi: 10.1016/j.ccr.2010.11.015 – ident: B19 doi: 10.1111/j.1750-3639.2002.tb00440.x – ident: B29 doi: 10.1093/neuonc/noq110 – ident: B26 doi: 10.1056/NEJMoa043331 – ident: B17 doi: 10.1097/01.jnen.0000263869.84188.72 – ident: B16 doi: 10.1111/j.1750-3639.2008.00129.x – ident: B28 doi: 10.1158/1078-0432.CCR-11-1274 – ident: B10 doi: 10.1215/15228517-2009-011 – ident: B5 doi: 10.1093/jnci/90.19.1473 – ident: B33 doi: 10.1200/JCO.2009.23.6497 – ident: B22a doi: 10.1200/JCO.2012.43.2674 – ident: B9 doi: 10.1007/978-3-642-84988-6 – ident: B20 doi: 10.1016/S0140-6736(04)17670-8 – ident: B30 doi: 10.1038/nature10866 – ident: B3 doi: 10.1200/JCO.2005.04.6078 – ident: B13 doi: 10.2307/2344317 – ident: B18 doi: 10.1002/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO;2-W – reference: 23149899 - Nat Rev Clin Oncol. 2012 Dec;9(12):670. doi: 10.1038/nrclinonc.2012.198. |
| SSID | ssj0014835 |
| Score | 2.6215737 |
| Snippet | Anaplastic oligodendroglioma are chemotherapy-sensitive tumors. We now present the long-term follow-up findings of a randomized phase III study on the addition... |
| SourceID | proquest pubmed pascalfrancis crossref highwire |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 344 |
| SubjectTerms | Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Biological and medical sciences Brain Neoplasms - drug therapy Brain Neoplasms - genetics Brain Neoplasms - radiotherapy Chemotherapy, Adjuvant Disease-Free Survival Follow-Up Studies Gene Deletion Humans In Situ Hybridization, Fluorescence Kaplan-Meier Estimate Lomustine - administration & dosage Lomustine - adverse effects Medical sciences Neurology Oligodendroglioma - drug therapy Oligodendroglioma - genetics Oligodendroglioma - radiotherapy Procarbazine - administration & dosage Procarbazine - adverse effects Tumors Tumors of the nervous system. Phacomatoses Vincristine - administration & dosage Vincristine - adverse effects |
| Title | Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951 |
| URI | http://jco.ascopubs.org/content/31/3/344.abstract https://www.ncbi.nlm.nih.gov/pubmed/23071237 https://www.proquest.com/docview/1273696675 |
| Volume | 31 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZT9tAEF5BKlV9qVp6QA-0lSqkKnGwvfY67luAIGhDgoiD8matLxTk2BFJVMFP6q_szPqE9H6xHMvedTzzzc7OSchHYcOyYpqewg07UgxDBzkIoFNs7qlmoOq28NGgfzbgJ2Pjy8ScbGw2alFLq6XX9u9-mlfyP1SFa0BXzJL9B8qWg8IFOAf6whEoDMe_onE3uF6BJryU4f7oOLibZgbKfjrDLl3ZDzSNX04TX8IZdEqsEZDnXcmkP5Bz8S3IPhlzB_pnNxFz0KmxkuswnsK-NcSiBlfxNJ3JRj79NLlSHJDozWNgovSbMp7L-MThhYO8ImBIZzVLb3JD10iWrda5nZd8XdeEy-zMNPHvWfkvu4PmUW_QPOgNnDyxCP5B5ck6uOgOjnqjLFHHE5VddnR6PpSX-zIQQFvcxXhyUAo5GDDP1rpIwxhbHZzU7R_Yi0JTdLXi2MKxVUS5YhRL8drD-mtnQtViugJibFJfAfJ1aFo3EEhxzrLalLlmwLISuWuLji77aV_7mEuq6W2DtbFJerXAFkEFD9bdMhpSt1TY45jmJnmkW6ABomp_-rX0hRmdrE1s8ea5sx1m3X84533lqih4jfG-YgHfI8p6tfx6MyWVKucZeZrzAO1mrP2cbITJFnl8lsd7bJG986yy-m2LOlWi4KJF9-h5VXP99gX5XkCB1qHQoiUQWhRgQGswoHUY0GlCJQxoCQNawYCuweAzLUFASxDQNKISBFSCgEoQUAkCKkFAJQhekvFxzzk8UfI2JIoPWsRS0RgzbZ9HXBjc57Df6YQGfHSP4W6fdQQT6Kr2OqZhBaGla8wMOFbNiyw1ilSzw16RRpIm4Tahnh-YWBCSC24ZwvJsj4mQq5rwWRTyINwh-wX9XD-v0Y-tYmIX9-o6Op4Phy5S3DWYixTfIZ_KJ-ZZfZrf3LtbsIS7mIk4BtLrLvAQ01zmAq_DDfcYpRyx4NAd8qHgHBeWIfQtiiRMVwuY0MLOoNyCe15nLFU9DXoEKMjWmz8N_5Y8qRD-jjSWN6vwPej8S29XQuIHOQr-AQ |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adjuvant+Procarbazine%2C+Lomustine%2C+and+Vincristine+Chemotherapy+in+Newly+Diagnosed+Anaplastic+Oligodendroglioma%3A+Long-Term+Follow-Up+of+EORTC+Brain+Tumor+Group+Study+26951&rft.jtitle=Journal+of+clinical+oncology&rft.au=VAN+DEN+BENT%2C+Martin+J&rft.au=BRANDES%2C+Alba+A&rft.au=SIPOS%2C+L%C3%A1szl%C3%B3&rft.au=ENTING%2C+Roelien+H&rft.date=2013-01-20&rft.pub=American+Society+of+Clinical+Oncology&rft.issn=0732-183X&rft.volume=31&rft.issue=3&rft.spage=344&rft.epage=350&rft_id=info:doi/10.1200%2Fjco.2012.43.2229&rft.externalDBID=n%2Fa&rft.externalDocID=27077255 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |